logo-loader

e-Therapeutics plc focused on commercialisation and making alliances

Published: 08:25 22 Mar 2016 EDT

e-Therapeutics plc (LON:ETX) is targeting partners to accelerate the development of its drug discovery engine, it told investors on Tuesday.

Malcolm Young, chief executive, tells Proactive that “making alliances with much larger companies is absolutely our foreground so that’s where we need to go, that’s where our frontier is, that’s where we need to make the advances.”

He adds “commercialisation as a focus in the company has really grown in significance in this last year,” and that the firm is looking for partnerships as a way to recognise the commercial value of both late stage and early stage products.

e-Therapeutics present at the Proactive One2One Investor Forum - October 26th

Ali Mortazavi, CEO of e-Therapeutics PLC (AIM:ETX, OTCQX:ETXPF), addressed the challenges of traditional drug discovery, emphasising its high risk, extensive timeline, and considerable cost at the Proactive One2One Investor Forum. Underlining the inefficiencies of this model, Mortazavi posed...

on 11/01/2023